In January, investors in Conatus Pharmaceuticals Inc. showed their displeasure with early stage pharmacokinetic and pharmacodynamic findings on the use of emricasan in patients with impaired liver function by sending the company's shares (NASDAQ:CNAT) into a 40 percent freefall.